<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099215</url>
  </required_header>
  <id_info>
    <org_study_id>PVS 03-001</org_study_id>
    <secondary_id>2009-011998-32</secondary_id>
    <nct_id>NCT01099215</nct_id>
  </id_info>
  <brief_title>Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)</brief_title>
  <acronym>TRIUMPH</acronym>
  <official_title>An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire Regenerative Medicine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire Regenerative Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic
      cellular therapy, delivered as a single injection following percutaneous transluminal
      (&quot;balloon&quot;) angioplasty and stent placement for the treatment of peripheral artery disease
      (PAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label dose escalation safety study of PVS-10200 in 30 subjects with
      peripheral artery disease (PAD) requiring balloon angioplasty and stent placement in the
      superficial femoral artery (SFA). The study will be completed sequentially in two dose
      cohorts of 10 subjects (low dose group, Cohort A) and 20 subjects (high dose group, Cohort
      B). A Data Safety Monitoring Board (DSMB) will conduct regular safety reviews.

      Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection
      to the perivascular region (external to the vessel) of the stented target lesion. The
      treatment will be administered within 24 hours after balloon angioplasty/stent placement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Major Adverse Events (MAEs)</measure>
    <time_frame>within 4 weeks after study procedure</time_frame>
    <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Events (MAEs)</measure>
    <time_frame>within 24 and 48 weeks from study procedure</time_frame>
    <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Up to 48 weeks from study procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, Laboratory Abnormalities</measure>
    <time_frame>Up to 48 weeks from study procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</measure>
    <time_frame>within 4 weeks from study procedure</time_frame>
    <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</measure>
    <time_frame>within 24 weeks from study procedure</time_frame>
    <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</measure>
    <time_frame>within 48 weeks from study procedure</time_frame>
    <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Binary In-stent Restenosis</measure>
    <time_frame>within 4 weeks from study procedure</time_frame>
    <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Binary In-stent Restenosis</measure>
    <time_frame>within 24 weeks from study procedure</time_frame>
    <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Binary In-stent Restenosis</measure>
    <time_frame>within 48 weeks from study procedure</time_frame>
    <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0-49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50-99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Reintervention of Target Lesion / Target Vessel</measure>
    <time_frame>up to 48 Weeks from study procedure</time_frame>
    <description>Survival analysis - outcome reported as patients requiring reintervention of the target lesion / vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Ankle-brachial Index</measure>
    <time_frame>within 4, 24 and 48 weeks from study procedure</time_frame>
    <description>ABI was calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm. This test is used to predict the severity of PAD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Exam</measure>
    <time_frame>within 4, 24 and 48 weeks from baseline</time_frame>
    <description>Changes in physical examination were compared to baseline: numbers of subjects presenting any new finding or worsening of abnormal findings compared to the screening examination are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Fontaine Class of Peripheral Artery Disease</measure>
    <time_frame>change from baseline to 4 weeks</time_frame>
    <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Fontaine Class of Peripheral Artery Disease</measure>
    <time_frame>change from baseline to 24 weeks</time_frame>
    <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Fontaine Class of Peripheral Artery Disease</measure>
    <time_frame>change from baseline to 48 weeks</time_frame>
    <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate -severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>PVS-10200</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVS-10200</intervention_name>
    <description>PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.</description>
    <arm_group_label>PVS-10200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has signed the informed consent document and patient information leaflet.

          2. Male and female subject ≥ 18 years of age at the time of consent.

          3. If female, the subject is (a) at least 1 year post-menopausal, or (b) surgically
             sterile, or (c) of child-bearing potential, with a negative serum pregnancy test
             result prior to study enrollment, who agrees to use adequate contraception for 6
             months. Adequate contraception is defined as abstinence or a reliable method of birth
             control (e.g., a hormonal contraceptive, intra-uterine device, implantable or
             injectable contraceptives (Norplant® or Depo-Provera®), diaphragm, or condom with
             spermicide).

          4. Subject has symptomatic peripheral arterial disease involving the superficial femoral
             artery, defined as Fontaine Class IIb, III and IV.

          5. Meets anatomic requirements based on biplane digital subtraction angiography performed
             at the time of intervention including:

               -  Stenosis of ≥ 50% or occlusion of the superficial femoral artery, and

               -  Target lesion length of ≤ 150 mm, and

               -  At least one patent (&lt; 50 % stenosis) tibioperoneal runoff vessel

          6. Target lesion is 7-15 cm in length.

          7. Subject is expected to stay in the same geographic area for at least 48 weeks.

          8. In the opinion of the investigator, the subject is able to understand and is willing
             to complete the study requirements.

          9. Subject is receiving a therapeutic dose of statin therapy (starting minimum of 7 days
             prior to intervention) and continuing for a minimum of 4 weeks post-intervention.

        Exclusion Criteria:

          1. Subject has acute limb ischemia.

          2. Subject has had prior revascularization of the target lesion.

          3. Subject has untreated inflow disease of the ipsilateral pelvic arteries (&gt; 50%
             stenosis or occlusion).

          4. The target lesion is located within an aneurysm or associated with an aneurysm in the
             vessel segment either proximal or distal to the target lesion(s).

          5. Subject has an unresolved thrombus within the target vessel.

          6. Additional percutaneous interventional procedures (cardiac/peripheral) are planned ≤
             30 days following the study procedure.

          7. Subject has suffered a hemorrhagic stroke ≤ 6 mo prior to the study procedure.

          8. Subject has a history of bleeding diatheses or coagulopathy.

          9. Subject is diagnosed with septicemia at the time of the study procedure.

         10. Subject is known to be seropositive for HIV.

         11. Subject has some other medical illness that may cause the subject to be non-compliant
             with the protocol.

         12. Subject has a known allergy to bovine or porcine products (i.e., heparin).

         13. Subject has a known allergy to collagen/gelatin products.

         14. Subject has had a severe reaction to contrast media.

         15. Subject has a known allergy or intolerance to anti-platelet medication (e.g.,
             acetylsalicylic acid or clopidogrel) or statin therapy.

         16. Subject has a history of IV drug use within 6 months prior to screening.

         17. Subject has a documented diagnosis of cancer within 2 years (24 months) prior to
             screening.

         18. Subject is a female who is pregnant, breast-feeding, or plans to become pregnant
             during the study.

         19. Subject is currently participating in another investigational drug, biologic or device
             trial, plans to participate in another investigational drug, biologic or device study
             during participation in this study, or has completed participation in another
             investigational drug, biologic or device trial within the last 30 days. Note: Subjects
             involved in extended follow-up trials for products that are currently commercially
             available and used as approved are not considered to be participating investigational
             trials.

         20. Subject is a staff member of any of the participating institutions or relative of a
             staff member.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Alsac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Europeen Georges Pompidou (HEGP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <results_first_submitted>June 28, 2013</results_first_submitted>
  <results_first_submitted_qc>January 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2014</results_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral artery disease</keyword>
  <keyword>percutaneous transluminal angioplasty</keyword>
  <keyword>stent</keyword>
  <keyword>balloon/stent</keyword>
  <keyword>superficial femoral artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study period was from 30 March 2010 (first patient’s screening visit) to 19 June 2012 (last patient’s Week 48 visit).
A total of 30 subjects were screened for study eligibility, of whom a total of 21 subjects were registered (i.e., enrolled) and treated with PVS-10200.
The study was conducted at 3 study centers in France</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose PVS-10200 (Cohort A)</title>
          <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
        </group>
        <group group_id="P2">
          <title>High Dose PVS-10200 (Cohort B)</title>
          <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at Screening</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="10.11"/>
                    <measurement group_id="B2" value="70.7" spread="7.67"/>
                    <measurement group_id="B3" value="66.0" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resting Ankle Brachial Index, Leg with Target Lesion</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.954" spread="0.164"/>
                    <measurement group_id="B2" value="0.851" spread="0.258"/>
                    <measurement group_id="B3" value="0.902" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fontaine Classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>STAGE IIB-MODERATE TO SEVERE CLAUDICATION(&lt;200M)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV - ULCERATION OR GANGRENE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Major Adverse Events (MAEs)</title>
        <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
        <time_frame>within 4 weeks after study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Adverse Events (MAEs)</title>
          <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Adverse Events (MAEs)</title>
        <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
        <time_frame>within 24 and 48 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Adverse Events (MAEs)</title>
          <description>Major Adverse Events are:
Death
Major amputation
Procedural related serious adverse events
Investigational product related serious adverse events</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <time_frame>Up to 48 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events, Laboratory Abnormalities</title>
        <time_frame>Up to 48 weeks from study procedure</time_frame>
        <population>Safety Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events, Laboratory Abnormalities</title>
          <population>Safety Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically Significant Laboratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
        <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 4 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
          <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
        <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 24 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
          <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
        <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 48 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Primary Patency of Superficial Femoral Artery (SFA)</title>
          <description>Primary patency was defined as duplex ultrasound peak systolic velocity [PSV] ratio ≤2.4.Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Binary In-stent Restenosis</title>
        <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 4 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Binary In-stent Restenosis</title>
          <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Binary In-stent Restenosis</title>
        <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 24 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Binary In-stent Restenosis</title>
          <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Binary In-stent Restenosis</title>
        <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
        <time_frame>within 48 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Binary In-stent Restenosis</title>
          <description>Binary restenosis relied on duplex ultrasound data with a Yes/No assessment with 0–49% being No (peak systolic velocity [PSV] ratio ≤2.4) and Yes being 50–99% (PSV ratio &gt;2.4), with the PSV ratio calculated as PSV from stenosis divided by the PSV from a normal segment of artery proximal to the stenosis.
Ultrasound data was obtained for each patient at each time point and had to be considered diagnostic and evaluable by the core lab; if it was not, then this analysis could not be done for that particular subject.</description>
          <population>Intention-to-Treat Population Analysis (Data was not available for all 21 subjects because it includes only ultrasound data obtained that was considered diagnostic and evaluable by the core lab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Reintervention of Target Lesion / Target Vessel</title>
        <description>Survival analysis - outcome reported as patients requiring reintervention of the target lesion / vessel</description>
        <time_frame>up to 48 Weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Reintervention of Target Lesion / Target Vessel</title>
          <description>Survival analysis - outcome reported as patients requiring reintervention of the target lesion / vessel</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="15.4%" lower_limit="29.00"/>
                    <measurement group_id="O2" value="2" spread="12.6%" lower_limit="52.86" upper_limit="65.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Ankle-brachial Index</title>
        <description>ABI was calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm. This test is used to predict the severity of PAD.</description>
        <time_frame>within 4, 24 and 48 weeks from study procedure</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Ankle-brachial Index</title>
          <description>ABI was calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm. This test is used to predict the severity of PAD.</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" spread="0.128"/>
                    <measurement group_id="O2" value="0.887" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" spread="0.172"/>
                    <measurement group_id="O2" value="0.842" spread="0.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" spread="0.193"/>
                    <measurement group_id="O2" value="0.857" spread="0.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Physical Exam</title>
        <description>Changes in physical examination were compared to baseline: numbers of subjects presenting any new finding or worsening of abnormal findings compared to the screening examination are reported</description>
        <time_frame>within 4, 24 and 48 weeks from baseline</time_frame>
        <population>Safety Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Physical Exam</title>
          <description>Changes in physical examination were compared to baseline: numbers of subjects presenting any new finding or worsening of abnormal findings compared to the screening examination are reported</description>
          <population>Safety Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Fontaine Class of Peripheral Artery Disease</title>
        <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
        <time_frame>change from baseline to 4 weeks</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>The Fontaine Class of Peripheral Artery Disease</title>
          <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STAGE IIB (Baseline) to STAGE I (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IIB (Baseline) to STAGE IIA (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE I (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE IV (Week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Fontaine Class of Peripheral Artery Disease</title>
        <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
        <time_frame>change from baseline to 24 weeks</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>The Fontaine Class of Peripheral Artery Disease</title>
          <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STAGE IIB (Baseline) to STAGE I (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IIB (Baseline) to STAGE IIA (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IIB (Baseline) to STAGE IIB (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE I (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE IV (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Fontaine Class of Peripheral Artery Disease</title>
        <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
        <time_frame>change from baseline to 48 weeks</time_frame>
        <population>Intention-to-Treat Population Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
          </group>
        </group_list>
        <measure>
          <title>The Fontaine Class of Peripheral Artery Disease</title>
          <description>CLASSIFICATION OF PERIPHERAL ATERIAL DISEASE ACCORDING TO FONTAINE Stage Clinical description I Asymptomatic IIA Mild claudication IIB Moderate –severe claudication III Ischemic rest pain IV Ulceration or gangrene</description>
          <population>Intention-to-Treat Population Analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STAGE IIB (Baseline) to STAGE I (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IIB (Baseline) to STAGE IIA (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IIB (Baseline) to STAGE IIB (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE I (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE IIB (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STAGE IV (Baseline) to STAGE IV (Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 March 2010 (first patient’s screening visit) to 19 June 2012 (last patient’s Week 48 visit)</time_frame>
      <desc>No increase in humoral sensitization seen after PVS-10200 treatment. Positive panel-reactive antibodies (PRA) findings seen at Wk 48 only in 2 subjects who also had positive PRA findings at Screening (i.e., sensitized prior to PVS 10-200 exposure). No treatment-emergent Adverse Events associated with humoral sensitization seen in either subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A</title>
          <description>Low dose PVS-10200 (6×10^5 cells/cm lesion)</description>
        </group>
        <group group_id="E2">
          <title>Cohort B</title>
          <description>High dose PVS-10200 (15×10^5 cells/cm lesion)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>WOUND NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>IN-STENT ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ANGIOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>LEG AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANGIOPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TOE AMPUTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>In-Stent Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Toe Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Company-specific confidentiality agreement</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small patient number, no control arm</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eric Goldberg, MD, Sr. Medical Director</name_or_title>
      <organization>Shire Regenerative Medicine</organization>
      <phone>(858) 754-5705</phone>
      <email>egoldberg@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

